Subscribe
yanlev-shutterstock-com-1
YanLev / Shutterstock.com
3 December 2015AmericasGerard Norton and Michael Montgomery

To dance or not to dance: biosimilar strategies post Amgen v Sandoz

The Biologics Price Competition and Innovation Act (BPCIA) is a landmark piece of legislation signed into law by the Obama administration in 2009. The BPCIA provides for a regulatory approval pathway for biosimilar products, which are like generic pharmaceuticals in that they are based on already approved ‘name brand’ biologics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Apotex ordered to provide 180 days’ biosimilar notice to Amgen
15 December 2015   Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.
Americas
US approves second biosimilar drug
6 April 2016   The US Food and Drug Administration has approved a biosimilar version of Janssen Biotech’s drug Remicade.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Apotex ordered to provide 180 days’ biosimilar notice to Amgen
15 December 2015   Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.
Americas
US approves second biosimilar drug
6 April 2016   The US Food and Drug Administration has approved a biosimilar version of Janssen Biotech’s drug Remicade.

More on this story

Americas
Apotex ordered to provide 180 days’ biosimilar notice to Amgen
15 December 2015   Parties are required to provide 180 days’ notice to a patent owner before marketing a biosimilar version of its drug, a US district court has ruled.
Americas
US approves second biosimilar drug
6 April 2016   The US Food and Drug Administration has approved a biosimilar version of Janssen Biotech’s drug Remicade.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
USPTO clarifies AI's role in patent eligibility